Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Earnings Results, Beats Expectations By $0.04 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its earnings results on Tuesday. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04, Zacks reports. Bayer Aktiengesellschaft had a positive return on equity of 15.44% and a negative net margin of 7.61%.

Bayer Aktiengesellschaft Stock Up 5.7%

Shares of Bayer Aktiengesellschaft stock traded up $0.45 during trading hours on Wednesday, hitting $8.36. 429,717 shares of the company’s stock traded hands, compared to its average volume of 713,563. Bayer Aktiengesellschaft has a twelve month low of $4.79 and a twelve month high of $8.70. The company has a market cap of $32.87 billion, a PE ratio of -8.62, a PEG ratio of 3.62 and a beta of 0.84. The company has a quick ratio of 0.73, a current ratio of 1.13 and a debt-to-equity ratio of 1.04. The stock has a 50 day simple moving average of $8.01 and a 200-day simple moving average of $7.72.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BAYRY. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Zacks Research downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.